Could Vital Therapies Inc (NASDAQ:VTL) See a Reversal After More Sellers Came In?

June 14, 2018 - By Hannah Black

Investors sentiment decreased to 0.93 in Q1 2018. Its down 1.92, from 2.85 in 2017Q4. It fall, as 11 investors sold Vital Therapies, Inc. shares while 16 reduced holdings. 10 funds opened positions while 15 raised stakes. 11.17 million shares or 7.13% more from 10.42 million shares in 2017Q4 were reported.
Vanguard Grp stated it has 0% of its portfolio in Vital Therapies, Inc. (NASDAQ:VTL). Balasa Dinverno Foltz Ltd Llc holds 25,625 shares. Bluecrest Cap Mngmt holds 0.01% of its portfolio in Vital Therapies, Inc. (NASDAQ:VTL) for 32,265 shares. Victory Cap Mngmt Inc owns 0.04% invested in Vital Therapies, Inc. (NASDAQ:VTL) for 2.99M shares. Susquehanna Gru Ltd Liability Partnership holds 194,525 shares or 0% of its portfolio. Wells Fargo And Mn has invested 0% in Vital Therapies, Inc. (NASDAQ:VTL). Bridgeway Cap Management holds 136,600 shares or 0.01% of its portfolio. Ironwood Financial Ltd Liability Corp owns 0.01% invested in Vital Therapies, Inc. (NASDAQ:VTL) for 860 shares. Blackrock has 954,715 shares for 0% of their portfolio. Balyasny Asset Mngmt Ltd accumulated 0% or 15,775 shares. Granahan Invest Mngmt Ma owns 556,212 shares for 0.27% of their portfolio. Dimensional Fund Advsrs Ltd Partnership stated it has 0% of its portfolio in Vital Therapies, Inc. (NASDAQ:VTL). Td Asset Management reported 0% in Vital Therapies, Inc. (NASDAQ:VTL). D E Shaw & Company Inc invested 0% in Vital Therapies, Inc. (NASDAQ:VTL). 233 are held by Daiwa Secs Gru Incorporated.

The stock of Vital Therapies Inc (NASDAQ:VTL) registered an increase of 1.62% in short interest. VTL’s total short interest was 6.36M shares in June as published by FINRA. Its up 1.62% from 6.26 million shares, reported previously. With 158,600 shares average volume, it will take short sellers 40 days to cover their VTL’s short positions. The short interest to Vital Therapies Inc’s float is 23.41%.

The stock increased 1.33% or $0.075 during the last trading session, reaching $5.725. About 148,060 shares traded. Vital Therapies, Inc. (NASDAQ:VTL) has risen 101.77% since June 14, 2017 and is uptrending. It has outperformed by 89.20% the S&P500.

Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell therapy targeting the treatment of acute forms of liver failure in the United States. The company has market cap of $242.56 million. The Company’s ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patient??s own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. It currently has negative earnings. The firm was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003.

More important recent Vital Therapies, Inc. (NASDAQ:VTL) news were published by: Globenewswire.com which released: “Vital Therapies Hosting Analyst R&D Day Today” on May 24, 2018, also Nasdaq.com published article titled: “Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)”, Nasdaq.com published: “Vital Therapies to Present at the Jefferies 2018 Global Healthcare Conference” on June 07, 2018. More interesting news about Vital Therapies, Inc. (NASDAQ:VTL) was released by: Equitiesfocus.com and their article: “Vital Therapies (NASDAQ:VTL) Earning Somewhat Favorable News Coverage, Analysis Shows” with publication date: June 14, 2018.

Vital Therapies, Inc. (NASDAQ:VTL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: